Development of off-the-shelf hematopoietic stem cell-engineered invariant natural killer T cells for COVID-19 therapeutic intervention.

ABSTRACT:

Background

New COVID-19 treatments are desperately needed as case numbers continue to rise and emergent strains threaten vaccine efficacy. Cell therapy has revolutionized cancer treatment and holds much promise in combatting infectious disease, including COVID-19. Invariant natural killer T (iNKT) cells are a rare subset of T cells with potent antiviral and immunoregulatory functions and an excellent safety profile. Current iNKT cell strategies are hindered by the extremely low presence of iNKT cells, and we have developed a platform to overcome this critical limitation.

Methods

We produced allogeneic HSC-engineered iNKT (^AlloHSC-iNKT) cells through TCR engineering of human cord blood CD34⁺ hematopoietic stem cells (HSCs) and differentiation of these HS

SUBMITTER: Li YR 

PROVIDER: S-EPMC8935266 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature